Healio compiles top psoriasis articles from 2024

Key takeaways:

• A Q&A concerning a celebrity controversy with tanning booths topped the list.
• Content involving nutrition, weight loss and stress followed closely behind.

As the year comes to a close, Healio Dermatology has assembled this year’s top psoriasis articles.

Q&A: Physician responds to Kim Kardashian using tanning booth to help psoriasis

When Kim Kardashian claimed that her tanning booth soothes her psoriasis early this year, the star received backlash from practitioners and fans alike. In the wake of this controversy, Azza Halim, MD, a board certified, multi-specialist physician with a focus in aesthetic and regenerative medicine, spoke to Healio about the dangers of using tanning beds as a therapy for psoriasis. Read more.

Early life nutrition could impact psoriasis risk

A higher risk for developing psoriasis was found in subjects who were fed formula as infants compared with those who were breastfed for at least the first 4 months of life, according to a Swedish study. Read more.

Oral roflumilast treatment may induce weight loss in patients with psoriasis

Approved in 2011 for the treatment of severe chronic obstructive pulmonary disease, oral roflumilast is a phosphodiesterase-4 inhibitor that frequently exhibits a side effect of weight loss — an outcome that may be appealing to patients who suffer from psoriasis and the condition’s accompanying comorbidity of obesity. Read more.

Stress may be associated with increased risk for psoriasis among men

In an interview with Healio, Marta Laskowski, MD, PhD, of the department of dermatology and venereology at the University of Gothenburg and Sahlgrenska University Hospital, discussed her study showing that low stress resilience in men may be linked to an increased risk for developing psoriasis or psoriatic arthritis. Read more.

Phase 3 data show Tremfya improves scalp psoriasis in patients with skin of color

Patients with skin of color that suffer from scalp psoriasis saw significant improvement in their disease severity, scalp itch and quality of life outcomes when treated with Tremfya, according to a phase 3 study. Read more.

Treatment advancements merit updates to dermatological disqualifiers in the military

Due to medical advancements, researchers are calling for an update to the U.S. Department of Defense’s policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military, according to a study. Healio spoke with four experts on the topic. Read more.

Treating psoriasis with biologics does not negatively affect COVID antibody production

The use of biologics to treat psoriasis does not affect antibody production after a patient has had a COVID infection or vaccination, according to a study. Benjamin Ungar, MD, of the department of dermatology at Icahn School of Medicine at Mount Sinai, discussed these results. Read more.

Program may help identify, manage cardiovascular risk in patients with psoriasis

Researchers have developed and piloted a centralized care coordination program to prevent cardiovascular events in patients with psoriatic disease, according to a study. Healio spoke with Joel M. Gelfand, MD, MSCE, the James J. Leyden Professor of Dermatology and Epidemiology at University of Pennsylvania and corresponding author of the study, about the results. Read more.

Spevigo approved to treat adolescents with generalized pustular psoriasis in US, China

On March 19, the FDA approved an expanded indication for Spevigo injection to treat generalized pustular psoriasis in pediatric patients aged 12 years and older weighing 40 kg or more, Boehringer Ingelheim announced in a press release. Read more.

Suicidal ideation, behavior rate low in psoriasis patients treated with bimekizumab

The long-term adjudicated suicidal ideation and behavior rate in patients with psoriasis treated with bimekizumab was low and within general psoriasis population ranges, according to a study. Read more.